Home > Insider Trading > Filing (0001209191-19-019703)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1293971	Bluebird Bio Inc.	BLUE	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1578696	David Davidson	C/O Bluebird Bio, Inc. 60 Binney Street Cambridge MA 02142	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-03-13	3,101	$5.50	34,717	No	4	M	Direct
Common Stock	Disposition	2019-03-13	1,700	$145.96	33,017	No	4	S	Direct
Common Stock	Disposition	2019-03-13	1,401	$146.95	31,616	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2019-03-13	3,101	$0.00	3,101	$5.50

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
13,050		2023-01-16	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2019.
The range in prices for the transaction reported on this line was $145.50 to $146.45. The average weighted price was $145.9594. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The range in prices for the transaction reported on this line was $146.65 to $147.20. The average weighted price was $146.9482. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years.